These results will be presented (Abstract CT130) on Tuesday, April 4 at the American Association for Cancer Research Annual Meeting 2017 in Washington, D.C.
The PANOVA trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields (TTFields) in patients with advanced pancreatic cancer whose tumors could not be removed surgically and who had not received chemotherapy or radiation therapy prior to the clinical trial. The second cohort included 20 patients who received a combination treatment regimen of TTFields plus nab-paclitaxel and gemcitabine. Read more . . .